Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor-negative|Stage IV Breast Cancer|Triple-negative Breast Carcinoma
Interventions: DRUG: everolimus|DRUG: eribulin mesylate|OTHER: pharmacological study|OTHER: laboratory biomarker analysis
Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)